Kymanox Adds Top Experts in Human Factors to Enhance Combination Product Capabilities
- Wall St ends up with Goldman; Dow posts biggest weekly rise since June
- Goldman Sachs (GS) Smashes Analyst 3Q Views on Robust M&A and Underwriting Activity
- Tesla (TSLA) Stock: Jefferies Raises Price Target on Higher Capacity Ramp and Sustained Demand, Berlin Giga Will Set New Design and Assembly Standards Says Analyst
- Food, fuels lift U.S. import prices in September
- SEC to Allow First Ever Bitcoin (BTC) ETF - Report
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
DURHAM, N.C., Oct. 7, 2020 /PRNewswire/ -- Kymanox, a full-service life sciences solutions provider supporting commercialization of vital medicines and treatments, today announced the addition of two new executives. Evan Edwards has joined as Principal Executive Advisor and QuynhNhu Nguyen as Director of Human Factors. These new hires bring a breadth of experience which build upon Kymanox experience in Human Factors and Combination Products including usability engineering program execution and management, product and process development, quality, regulatory, strategy, clinical and medical affairs, and risk mitigation.
"I am pleased to welcome two of the top names in the industry to the Kymanox team," said Stephen M. Perry, CEO. "Many organizations are struggling with development and commercialization activities related to Human Factors which often results in wasted time and budget. Our clients will now benefit from the exceptional talent and experience that Evan and QuynhNhu bring to Kymanox. We've enhanced our capabilities to become the world-class leader in Human Factors Regulatory and Program Strategy for combination products in the biotechnology and pharmaceutical industries."
With over 17 years of experience in the pharmaceutical and medical device industries, Evan Edwards joins Kymanox as Principal Executive Advisor working directly with Perry and advising on growth strategies for Kymanox as well as co-leading the HUman factors Regulatory And Strategy (HURAS) practice. He was the cofounder of kaléo Inc. and co-inventor of the AUVI-Q (epinephrine injection, USP) and kaléo's drug delivery device technologies. He has extensive experience in drug device combination products and is named on over 200 patents, issued and pending, both domestically and abroad. Edwards is a subject matter expert in Usability Engineering, Design Controls, Combination Products, Operations, Industrialization, Quality Systems, Executive Leadership, Pre-Approval Inspection Readiness, Human Factors, Intellectual Property Strategy and Invention and Design. Edwards holds a B.S. in Mechanical Engineering from University of Virginia and an M.S. in Systems Engineering from University of Virginia with a concentration on Human Factors Engineering.
QuynhNhu Nguyen joins Kymanox as Director of Human Factors, working with Edwards and also providing leadership for the HURAS practice. With over 15 years in Human Factors Regulatory and Evaluation at the FDA, Nguyen served as Associate Director of Human Factors within the Division of Medication Error Prevention and Analysis (DMEPA), part of the Center for Drug Evaluation and Research (CDER) where she co-led development of the Human Factors program and provided oversight for review of over 500 submissions. She also led Human Factors Reviews at the FDA Center for Devices and Radiological Health (CDRH) with over 400 reviews of medical products. Nguyen has been recognized with 26 US Public Health Service Awards and Medals, and 17 Formal FDA and Center Recognitions. She will serve as a subject matter expert for Kymanox in Human Factors/Usability Engineering, Program Management, Combination Products, Human Factors Regulatory Strategy, Patient Safety, Risk Management, and Medication Error Prevention. Nguyen holds a B.S. in Biomedical Engineering from George Washington University and a M.S. in Systems Engineering from John Hopkins University.
To learn more about how Kymanox can help you with combination products in general or our capabilities in Human Factors Regulatory and Program Strategy for the medical device, biotechnology and pharmaceutical industries, contact us at HURAS@kymanox.com or visit www.kymanox.com today.
About Kymanox: Your Life Science Solutions PartnerKymanox is a premier one-stop solutions provider supporting development and commercialization of vital medicines and treatments for people to live better, love longer, and GET MORE DONE. Leveraging a corporate DNA of Ideal Knowledge Transfer™, the Kymanox team partners with global clients to facilitate development and delivery of products with optimized safety, quality, efficacy, accessibility, and efficiency. As a true life science solutions partner, the company operates in the Biotechnology, Pharmaceutical, Medical Device, and Combination Product industries. Kymanox offers a broad range of professional services with turnkey project delivery, serving clients globally from the corporate headquarters in Durham (RTP), North Carolina and branch offices across the US including Boston, Chicago, and New Jersey. Learn more about Kymanox at https://kymanox.com/.
View original content to download multimedia:http://www.prnewswire.com/news-releases/kymanox-adds-top-experts-in-human-factors-to-enhance-combination-product-capabilities-301148069.html
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IRA Capital Acquires Class-A Beverly Hills Creative-Office for $153 Million
- U.S. FDA Approves Cyltezo® (adalimumab-adbm) as First Interchangeable Biosimilar with Humira®
- Apollo Career Center Identifies and Addresses Data Security Incident
Create E-mail Alert Related CategoriesPRNewswire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!